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Abstract
Canine rabies can be effectively controlled by vaccination with readily available, high-quality vaccines. These vaccines
should provide protection from challenge in healthy dogs, for the claimed period, for duration of immunity, which is often
two or three years. It has been suggested that, in free-roaming dog populations where rabies is endemic, vaccine-induced
protection may be compromised by immuno-suppression through malnutrition, infection and other stressors. This may
reduce the proportion of dogs that seroconvert to the vaccine during vaccination campaigns and the duration of immunity
of those dogs that seroconvert. Vaccination coverage may also be limited through insufficient vaccine delivery during
vaccination campaigns and the loss of vaccinated individuals from populations through demographic processes. This is the
first longitudinal study to evaluate temporal variations in rabies vaccine-induced serological responses, and factors
associated with these variations, at the individual level in previously unvaccinated free-roaming dog populations. Individual-
level serological and health-based data were collected from three cohorts of dogs in regions where rabies is endemic, one in
South Africa and two in Indonesia. We found that the vast majority of dogs seroconverted to the vaccine; however, there
was considerable variation in titres, partly attributable to illness and lactation at the time of vaccination. Furthermore,.70%
of the dogs were vaccinated through community engagement and door-to-door vaccine delivery, even in Indonesia where
the majority of the dogs needed to be caught by net on successive occasions for repeat blood sampling and vaccination.
This demonstrates the feasibility of achieving population-level immunity in free-roaming dog populations in rabies-endemic
regions. However, attrition of immune individuals through demographic processes and waning immunity necessitates
repeat vaccination of populations within at least two years to ensure communities are protected from rabies. These findings
support annual mass vaccination campaigns as the most effective means to control canine rabies.
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Introduction
Canine-mediated rabies is a viral zoonosis, causing at least
55,000 human deaths every year [1]. Mortality from rabies is
highest in less developed communities in Asia and Africa, where
domestic dogs are free-roaming [2–8]; with increasing evidence
that the majority are owned [2,3,6,9,10] and, thus, generally
accessible for vaccination [11,12].
Canine rabies can be effectively controlled by vaccination [13–
16] using readily available, high potency (antigenic value $1 IU/
ml), inactivated cell-culture vaccines. These vaccines should
provide protection from challenge in healthy dogs for the claimed
period for duration of immunity [17], which is often two or three
years. In free-roaming dog populations, vaccine-induced protec-
tion from rabies may be compromised for several reasons. These
include: (a) insufficient vaccine delivery during vaccination
campaigns [11], (b) lack of repeat vaccination campaigns, with
loss of vaccinated individuals from populations through demo-
graphic processes [18,19], and a substantial proportion of dogs
probably vaccinated only once in their lifetime [20], despite them
often living beyond three years of age [19]; and, (c) the possibility
of immuno-suppression through malnutrition, infection or other
stressors [21–23], which may reduce the proportion of dogs that
seroconvert or the duration of immunity of those dogs that
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seroconvert. These constraints may result in a decline in the
vaccination coverage between campaigns to below 20–45%, the
threshold necessary to control rabies [24]. Consequently, investi-
gating the effectiveness of vaccination campaigns under field
conditions is critical.
The adaptive (B-cell humoral and T-cell cell-mediated) immune
response to vaccination is complex. The humoral response
generates virus neutralizing antibody (VNA), the primary correlate
of protection induced by viral vaccines [18,25–27]. Cell mediated
immunity (CMI) is also important for the development of vaccine-
induced immunity [28–30] and acts in synergy with the humoral
response [27]. Ongoing protection from challenge depends on the
persistence of long-lived plasma cells, continuing to generate
antigen-specific antibody, and B- and T- memory cells. The
primary antibody response following vaccination generally corre-
lates with the strength of the memory response (B- and T-cell) and,
thus, the ability to induce secondary responses to subsequent
challenge [27,31–35]. In healthy dogs the quality of the primary
immune response to vaccination depends on several factors,
including the type of vaccine, with modified-live vaccines generally
inducing superior responses, the route of administration, and the
dose of vaccine antigen [25,27,32,33,35–37].
Laboratory challenge studies in healthy dogs support these
observations. Following seroconversion, protection from rabies
virus challenge correlates with peak VNA titre and final titre prior
to challenge for inactivated, DNA and modified-live vaccines, with
increased susceptibility to challenge once titres drop to near
negligible levels (VNA titres ,0.1 IU/ml or mouse serum
neutralizing antibody titres ,1:2 dilution) [31–35,37–41]. These
studies used comparable antibody assays [42,43] and virus
challenge doses. Titres measured repeatedly over 3–4 years
initially peaked and then declined rapidly, followed by a more
gradual decline [31,33,34,44]. While a titre of 0.5 IU/ml
demonstrates seroconversion following vaccination [45], the
approximate threshold for protection following seroconversion
may be 0.1 IU/ml [34,37,40,46]. However, in the aforementioned
experimental studies, only a proportion (,40%) of dogs with
measureable titres following vaccination, but with negligible titres
at the time of challenge succumbed to challenge, highlighting the
importance of previously activated B- or T- cells allowing rapid
response to challenge.
Although the same relationship between VNA titre and
protection from challenge is expected in immuno-suppressed dogs
as in healthy dogs [21,23], no systematic comparison has been
published to date. Reduced humoral immune responses have been
shown in malnourished experimental dogs [22] and Gambian
children vaccinated with human diploid-cell rabies vaccine [47],
and pet dogs with anaemia or intestinal parasites vaccinated
against rabies [37,48]. Several studies have evaluated the immune
response in previously unvaccinated, mostly healthy pet dogs to
high potency, inactivated rabies vaccine under field conditions
[48–54]. All of these studies report variable VNA titres up to 12
months following vaccination, including a proportion of dogs with
titres #0.1 IU/ml (and generally a larger [17% to .42%]
proportion with titres ,0.5 IU/ml). These observations have
serious implications for free-roaming dogs where their health
status is more likely to be compromised. However, with the
exception of one study in Peru [55], no study has evaluated
variations in vaccine-induced VNA in previously unvaccinated
free-roaming dogs where rabies is endemic. Furthermore, no study
has properly evaluated the factors associated with these variations.
Cell mediated immunity is technically difficult to measure under
field conditions [28,56], however peripheral blood lymphocyte
counts, which are predominately T-cells [57], may provide a
straightforward, indirect assessment of CMI. Together with
cytokine assays and measures of blastogenic responses of
lymphocytes to mitogen, lymphocyte counts were used to assess
immunomodulation in healthy dogs in response to vaccination
[58–60] and protein-calorie malnutrition [22], and in humans in
response to protein-calorie malnutrition [61]. In dogs, malnutri-
tion induced declines in immunoglobulin and lymphocyte function
and counts. Therefore, lymphocyte counts together with rabies
vaccine-induced titres and nutritional status may correspond to the
overall immune status of an individual and susceptibility to
infection.
This study focused on evaluating temporal variations in vaccine-
induced VNA, and factors associated with these variations, in
three previously unvaccinated, owned free-roaming dog popula-
tions in South Africa and Indonesia, to better understand their
effect on vaccination coverage. In addition, the efficiency of
vaccine delivery and loss of vaccinated individuals from the
cohorts were also assessed.
Materials and Methods
Study populations
See Table S1 for a summary of the methodology. Data were
collected from three cohorts of dogs, one in South Africa, and two
in Indonesia. The cohorts were part of a larger ecological study
that commenced in March 2008 [19]. The South African cohort
was located in Zenzele, an informal settlement 10 km west of
Johannesburg (26.15uS and 27.41uE). In Indonesia the cohorts
were located in the study areas of Kelusa (8.26uS and 115.15uE)
and Antiga (8.30uS and 115.29uE), two villages on the island of
Bali. Kelusa, composed of six banjars (sub-villages), is inland. The
study area encompassed the entire village except for Banjar
Yehtengeh, separated from the rest of the village by rice fields and
jungle, the southern half of Banjar Kelikikawan and the
households scattered along the main road leading into the village.
Antiga, a large village of six banjars, is located on the east coast.
The bulk of the households are clustered into two banjars (Kaler
and Kelod). The study area encompassed all of Kaler and Kelod.
An additional area (Banjar Ketug) included households scattered
Author Summary
Canine-mediated rabies is a horrific disease that claims
tens of thousands of human lives every year, particularly in
Asia and Africa. The disease can be effectively controlled
through mass vaccination of dogs with high-quality
vaccines; however, questions remain over the effectiveness
of vaccination where the health status of free-roaming
dogs may be compromised and the life expectancy and
access to these dogs may be limited. This study evaluated
rabies-vaccine induced immune responses and vaccine
delivery in previously unvaccinated, free-roaming dog
populations in two rabies endemic regions in Asia and
Africa, to better understand the effectiveness of vaccina-
tion campaigns. We found that the majority of dogs
seroconverted to the vaccine regardless of health status.
Excellent vaccination coverage was achieved through
community engagement and door-to-door vaccine deliv-
ery, even where the majority of the dogs needed to be
caught by net for vaccination. However, attrition of
immune individuals through demographic processes and
waning immunity reinforces the importance of frequent
and regular vaccination campaigns to ensure effective
vaccination coverage is maintained.
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along a 2.7 km stretch of road winding through the jungle north of
Kaler and Kelod. Rabies is endemic in Indonesia and South
Africa, with outbreaks occurring in Bali in 2008 and Gauteng
Province in 2010.
The Zenzele research cohort included every available dog in the
entire township (which was the study area) in February 2010 that
had not been previously vaccinated by the Department of
Agriculture (DoA) during a vaccination point (VP) on the outskirts
of the township in October 2009 (Table S2). All the dogs
vaccinated by the DoA were identified within one week of the one
day VP through a rapid door-to-door search, with verification by
owners and inspection of certificates. The DoA had also set-up a
VP on the outskirts of Zenzele in May 2006, thus vaccination
history and certification were checked with each owner at the start
of the study. VNA titres were also evaluated for anamnestic
responses to vaccination consistent with previous vaccination.
The Bali research cohorts included every available dog in the
study areas of Kelusa and Antiga in January 2010 that had not
been previously vaccinated by the Department of Livestock (DoL)
as described below (Table S2). Prior to a rabies outbreak in 2008,
vaccination against rabies was illegal in Bali and there had been no
systematic vaccination programs in either village prior to
commencement of the study. Vaccination points were set up by
the DoL in two banjars in Kelusa in December 2009 and in one
banjar outside of the study area in Antiga in February 2010. The
VPs were poorly attended because of community awareness of the
research vaccination program and because the owners could not
readily handle their dogs. In Kelusa, 16 dogs from the study area
attended the vaccination points. In Antiga only three dogs from
the study area attended the vaccination point.
All of the dogs resident in the study area were owned and had
been previously identified by household, name and appearance
through intensive monitoring by direct observation and survey
since March 2008. Intensive monitoring of all of the dogs in the
study area continued until April 2011. Therefore, all of the dogs in
the study population were readily identified at the individual level
during the study period. There was no evidence for a resident
population of unowned dogs [19,62]. All dogs in their third month
of life or older were photographed (standardised dorsal and lateral
views). Pups in their first or second month of life were recorded but
not photographed. The same enumerators had tracked the
majority of the cohorts at the individual level since March 2008
and were familiar with the dogs.
Vaccination and sampling
Vaccine delivery was door-to-door for the research cohorts, and
households were revisited repeatedly until the dog was caught for
vaccination and blood sampling, or it was apparent that the dog
could not be caught or the owner would not be available to give
consent. A dog was also excluded from the study if the owner
declined consent, the dog did not remain calm during restraint,
there was a high index of suspicion that the dog may bite, or it was
apparent the dog had a clinical condition that might have
deteriorated as a result of restraint.
All the dogs were carefully restrained by experienced personnel
using the correct equipment and under the direct supervision of a
veterinarian. In Zenzele, dogs were gently restrained with a leash
and soft muzzle. In Bali most dogs could not be safely restrained
by leash and muzzle and required restraint by net. Vaccinations
and blood sampling were undertaken by experienced veterinari-
ans. High-quality, sterile consumables (i.e. needle, syringe and
blood tubes) were used for each vaccination and blood sample.
Dogs in the research cohorts were vaccinated with 1 ml of Rabisin
[63], an inactivated rabies vaccine containing at least 1 IU/ml of
rabies virus glycoprotein (GS57 Wistar strain) with an aluminium
hydroxide adjuvant. Vaccine was administered subcutaneously
into the neck or shoulder region. The vaccine cold chain was
carefully preserved.
Rabisin and Galaxy DA2PPv, a polyvalent vaccine against
common infectious pathogens, was administered by the DoA
during the October 2009 VP in Zenzele. Some dogs vaccinated at
the VP may have received ivermectin. The DoL administered
Rabisin during the February 2010 VP in Antiga, and Rabivet
Supra 92, a locally produced cell-culture vaccine, during the
December 2009 VP in Kelusa. Vaccine administration and storage
by the local authorities were not observed.
Different blood sampling schedules were required for Zenzele
and Bali given the different methods of restraint and because the
rabies outbreak in Bali escalated during 2009, forcing vaccination
to be undertaken 6 months earlier than planned. Every dog in
each research cohort, including neonates, was vaccinated at the
start of the study (day 0) (Zenzele n = 259, Kelusa n= 284 and
Antiga n= 259 vaccinated [Table S2]), and every available dog
from about 6–8 weeks of age was blood sampled (see Table 1 and
Table S3 for the number of dogs blood sampled at each time
point).
Blood was collected from the Zenzele research cohort on day 0
(immediately prior to vaccination) and then approximately 30, 90,
180 and 360 days following vaccination. The dogs vaccinated by
the DoA were also blood sampled 8–10 days after the VP. Samples
were then collected approximately 30, 90, 180 and 360 days
following the VP. In Zenzele, only those dogs that had been
vaccinated were blood sampled. Rabies-vaccine induced VNA was
measured at each time point. Complete blood counts (CBCs) were
measured on days 0, 180 and 360 for the research cohort.
In Bali, samples were collected on day approximately 180 and
360 following vaccination. Every available dog, whether vaccinat-
ed or not, was blood sampled at both time points and analysed for
rabies-vaccine induced VNA. Unvaccinated dogs constituted the
control group, and included those dogs not caught for vaccination
on day 0 and those that arrived into the study populations after
day 0. The sixteen dogs in Kelusa and three dogs in Antiga
vaccinated by the DoL, in December 2009 and February 2010
respectively, were blood sampled at the same time as the research
cohort.
In all the sites, households were visited in approximately the
same order at each time point, so the number of days between
samples were similar for each dog.
For each sample, 5–7 ml of blood was collected from the jugular
or cephalic vein and divided into plain and ethylene diamine-
tetraacetic acid (EDTA) containing blood tubes. The blood tubes
were immediately coded by date, house number and dog
identification and placed in cool boxes with ice packs. Serum
was separated by centrifugation within 8 hours of collection and
refrigerated at 4–6uC for up to 48 hours prior to freezing. All the
sera were transported frozen in dry shippers to the Weybridge
Animal Health Veterinary Laboratory Agency in the United
Kingdom for fluorescent antibody virus neutralization (FAVN)
assays. EDTA whole blood samples were refrigerated and then
tested within 48 hours of collection for CBCs. Approximately
10 grams of faeces was collected manually on day 0 from 107 dogs
randomly selected from the Zenzele cohort for routine analysis.
Upon collection, the faecal sample pots were similarly coded and
kept in the cool boxes, then refrigerated until being tested.
Complete blood counts and faecal analysis were undertaken by the
Faculty of Veterinary Science, University of Pretoria. Suitable
laboratory facilities were not accessible in Bali for these tests.
Finally, 32 dogs from Kelusa and Antiga combined were selected
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on day 180 from those dogs diagnosed with generalised dermatitis
during the preceding survey for deep skin scrapes (DSS) from
affected areas of skin to determine the prevalence of Demodex spp.
See text S1 and text S3 for an explanation of sample selection for
the DSS and faecal analysis.
Covariates
Factors that may influence the immune response to rabies
vaccine were selected on their measurability under field condi-
tions, particularly by vaccinators. These factors had been
previously quantified at the individual level as part of the larger
ecological study that commenced in March 2008, and the methods
used to quantify the factors are described elsewhere [19]. In
summary, the factors were categorical and measured by direct
observation and questionnaire at the time of vaccination (gender,
age class, pregnancy, lactation, sterilisation status [Bali only],
intestinal parasites [Zenzele only]) or within 6 weeks of vaccination
(body condition, clinical signs associated with serious illness,
protein intake [Bali only], and generalised dermatitis [Bali only])
[21,22,37,47,48,64–67]. See text S2 and Table S19 for a detailed
description of the covariates. Time (points) was treated as a
continuous variable.
Analytical methods
Laboratory tests. VNA was measured by fluorescent anti-
body virus neutralization (FAVN), a method prescribed by the
Office International des Epizootes (OIE) [42]. In order to evaluate
the variability in titres, including #0.1 IU/ml, the assay was
modified to include a two-fold dilution with reciprocal dilutions
ranging from 2 to 4096. Fifty percent endpoint titres, estimated by
the Spearman-Karber method [68], were converted into interna-
tional units (IU/ml) by comparison with a standard serum. All
samples were tested within two weeks of thawing and re-frozen
within three weeks of testing. Except during assay preparation, all
thawed samples were refrigerated.
All of the samples from the same dog were tested within the
same batch. Consequently, samples from each dog were frozen for
a variable amount of time between collection and testing and a
proportion of the samples were stored for over 12 months. To
evaluate the effect of storage time and freeze-thaw cycles on titres,
25 samples were randomly selected from the first batch tested.
These samples had been frozen (220uC) for over 2 years between
the initial and repeat tests.
To rule out cross-reaction with Lyssaviruses other than Rabies
Virus (RABV), 30 samples were randomly selected from the
Zenzele research cohort (day 0) and 60 from the Bali research
cohorts and controls (day 180 and 360) combined and tested
against Lagos Bat Virus (LBV), an antigenically divergent virus
from Phylogroup II Lyssaviruses [69].
Complete blood counts were determined by an automated cell
counter (ADVIA 2120 Siemens) using impedence counting, flow
cytochemistry, laser light scattering and validated veterinary
package software. The differential leukocyte counts were con-
firmed by manual counting.
Deep skin scrapes and faecal samples were evaluated using
standard protocols [65,70] (text S1).
Statistical methods. A range of models were used to explore
the relationship between time after vaccination and physiological
and health status at the time of vaccination on titre. Correlation
coefficients for titres and log titres were determined for a
combination of time points (i.e. day 30, 90, 180 and 360) for the
vaccinated dogs in Zenzele. This suggested that dogs with higher
peak VNA titres also had higher titres towards the end of the study
period.
Linear mixed effects models were fitted to the longitudinal data
from the vaccinated dogs in the research cohorts using the nlme
package in R (3.0.1) [71,72]. Dogs vaccinated by the local
authorities in Zenzele in October 2009, Kelusa in December 2009
and Antiga February 2010 were excluded from these analyses
because the administration of a standardised dose of Rabisin was
not observed. The response variable, of VNA titre (here after
referred to as ‘‘titre’’) following vaccination, was modelled as the
natural log of the titre (determined by Box-Cox transformation)
expressed in IU. Therefore, baseline (day 0) titres were dropped
from the Zenzele models and the unvaccinated (control) dogs were
excluded from the Bali models. Explanatory variables included
time (points) and the covariates described under Covariates (also
see text S2 and Table S19) as fixed effects, and dog as a random
effect. All individuals with complete information for the variables
of interest were included in the models. Forward and backwards
stepwise regression compared the full range of covariates and their
biologically plausible interactions to the null model. The models
with the lowest Akaike’s Information Criteria (AIC) for the highest
number of observations were retained.
Models were first fitted to each cohort separately. The Bali
cohorts were then combined and the model refitted with dog
nested within study area (i.e. village) as a random effect. Finally, all
the research cohorts were combined and the models refitted. Each
of these models were fitted with and without upper outliers (i.e.
day 30 titres$128 IU/ml for 7 dogs in Zenzele, and day 180 titres
$11.3 IU/ml for 4 dogs in Kelusa and 15 dogs in Antiga) in order
to exclude dogs from the analysis that may have been previously
vaccinated by the DoA in Zenzele in May 2006, as part of
vaccination campaigns outside of Kelusa and Antiga, or privately
by their owners. Upper outliers were defined according to
vaccination history, breed, age, source, geographical location
and post-vaccinal titres (further described under Assessment of
prior vaccinations in the Results).
Table 1. The number of dogs in the research cohorts and the number of unvaccinated controls in Bali that were blood sampled at
each time point (this table is reproduced with additional information in the Supporting Information Table S3).
day 0* day 30 day 90 day 180 day 360
Zenzele vaccinated dogs 190 183 148 134 103
Kelusa vaccinated dogs _ _ _ 168 124
Kelusa unvaccinated dogs _ _ _ 70 79
Antiga vaccinated dogs _ _ _ 163 126
Antiga unvaccinated dogs _ _ _ 35 49
*day 0 immediately prior to vaccination for the research cohort.
doi:10.1371/journal.pntd.0003160.t001
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The models take the form:
ln Yij
 
~b0zb1Xij1z   zbpXijpzbpz1X 2ijpzhizeij ,
where Yij is titre and Xijk (k~1, . . . ,p) are the covariates for
observation j~1, . . . ,ni on individual i~1, . . . ,m, where the final
covariate (Xijp) is time. Hence, time is modelled as a quadratic
curve (Figure 1). The vector b~ b0, . . . ,bpz1
 
is a vector of
regression coefficients, and the vector h~ h1, . . . ,hmð Þ corresponds
to a set of individual-level random effect terms, such that
Pm
i~1
hi~0. Finally the error terms eij*N 0,s2
 
.
This model was fitted to the full data set for Zenzele, which
included all the time points (i.e. day 30, 90, 180 and 360). The
data set included one to four data points for each individual
depending on the availability of the individual for blood sampling
during the study period. Times were adjusted by 30 days to allow
the model intercepts to correspond to day 30 (peak) titres. A model
using an exponential decay (rather than quadratic) over time was
also fitted, however the quadratic model provided a marginally
better fit to the data across this range, and so only the results from
the quadratic model are reported here.
The Bali data contained only one or two data points for each
individual (i.e. day 180 and 360), and so instead a linear
relationship to time was used (instead of quadratic). To facilitate
comparisons with the Bali cohorts, linear models were fitted to
truncated data sets for Zenzele (i.e. day 90 or 180 to 360), and the
time (points) were adjusted to allow the intercepts to correspond to
titres on day 90 or 180 respectively. Experimental studies report a
spike in titre immediately following vaccination, followed by a
prolonged, slow decline in titre [34]. Although a quadratic
relationship with time fits the Zenzele data set well over the
observed range of the data (Table S18), it does not monotonically
decrease over time and hence is a poor choice for predictions
beyond the range of the data. Exponential decay models do
decease monotonically, but do not have heavy enough tails given
how we would expect the titres to decay outside the range of the
data, based on previous studies [34]. Fitting alternative models to a
skewed distribution with heavy tail for predictions is challenging
given that there is insufficient data in the extremes in order to
robustly estimate the tail. Therefore, linear models, fitted to
Zenzele data sets that exclude peak (day 30) titres, were selected to
approximate prolonged, slow declines in titre for predictions in
GMT beyond the last time point (Table S17).
To explore the relationship between the natural log of the day
30 (peak) titres and the covariates described under Covariates and
lymphocyte and eosinophil counts on day 0, 180 and 360 for
Zenzele, linear models were fitted to these data and model
selection performed using stepAIC with the MASS package in R
(3.0.1) [73]. These models were equivalent to an analysis of
variance. An association between eosinophil counts and antibody
titres at each time point was also assessed.
The final models were checked for violation of constant
variance and normal error distribution assumptions.
Mann-Whitney tests were used to compare titres between (a)
vaccinated dogs in Zenzele, Kelusa and Antiga for the same time
points, (b) unvaccinated dogs in Kelusa and Antiga for the same
Figure 1. Declines in titre in the Zenzele research cohort. Titres of all the dogs (n = 82) in the Zenzele research cohort that were blood sampled
all at four time points (30, 90, 180 and 360 days after vaccination). Upper outliers (i.e. the dogs with day 30 titres $128 IU/ml) are excluded. Titres in
IU/ml are shown on the log scale. The geometric mean titre is shown in red.
doi:10.1371/journal.pntd.0003160.g001
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time points, and (c) dogs present in Zenzele in May 2006 and those
that arrived into the population after May 2006. The natural log of
the titre was used for these comparisons. The Mann-Whitney test
was also used to compare peak (day 30) titres between dogs with
day 360 titres ,0.5 IU/ml and $0.5 IU/ml in Zenzele, and the
cube root transformation of the titre was used to stabilise the
variance according to a Box-Cox transformation. Population
structures were stable [19], therefore age-specific life expectancies
were estimated, by standard analysis of vertical life tables
[9,74,75], from the observed ages of the entire study population
at the end of the study period.
Ethics
The study was approved by the Ethics Committee, University of
Cambridge [DVM/EC/1-2010], and the Animal Ethics Com-
mittee, University of Pretoria [v025-10 AUCC]. Permits to collect
demographic data were granted by the Ministry for Research and
Technology (RISTEK), Indonesia [03923/SIP/FRP/SM/IV/
2010]. Blood samples were collected under the auspices of the
Faculty of Veterinary Medicine, Udayana University, Bali
[RG49780], and permits for vaccination and blood collection
were granted by the Balinese provincial and regencies Depart-
ments of Livestock, the districts Centres of Animal Health (UPT)
[RG49780], and Kesbang, Pol and Linmas (the combined
Agencies for National Unity, Politics and Protection) [070/
607.D.III and 070/015/D.II]. In all of the sites, informed consent
was obtained prior to each survey and blood test from the
community leaders and owners, who were kept fully informed of
the purpose, approach and progress of the study. Vaccination and
blood sampling were only carried out with the owner, or
responsible adult delegated by the owner, present and their
express consent.
Results
General description of the study populations
Almost all of the dogs in the study populations were owned but
free-roaming, with ,10% confined continuously or frequently
during the study period March 2008–April 2011. There was an
approximately even ratio of male to female dogs in Zenzele, but
the ratio was skewed towards males (approximately 75%) in Bali.
Less than 2% of dogs were sterilised in Zenzele, but castration of
juvenile male dogs by community members was common in Bali
(approximately 14% in Kelusa and 27% in Antiga) [19]. Life
expectancy was at least 3 years for the majority of dogs in the study
populations (Table S4 and Figures S1a–S1c).
Vaccination coverage
High vaccination coverage was achieved through door-to-door
vaccine delivery: 82% (259/315) in Zenzele, 81% (284/351) in
Kelusa and 79% (259/327) in Antiga. Similar coverage (75–86%)
was achieved in Bali for blood sampling at day 180 and 360,
despite many of the dogs having been caught on at least one
previous occasion (Table S2). The characteristics of dogs that
avoided capture are described in Table S5. The sex ratio and age
distribution of these dogs were similar to the overall population
(Figures S1a–S1c).
Attrition of the cohorts occurred during the study period
through mortality, particularly of neonates, but also through the
relocation and disappearance of dogs [19]. Of the 259 dogs
vaccinated in Zenzele at the start of the study, 103 (40%) were
sampled at the last time point. Similar proportions were recorded
in Kelusa (44%, n= 124) and Antiga (49%, n= 126) (Tables S2
and S3).
Assessment of prior vaccinations
In the Zenzele research cohort, upper outliers were defined as
dogs with peak titres (on day 30) of 128 IU/ml or greater (n = 7).
Some of these dogs were either in the study area in May 2006 or
may have been previously independently vaccinated by their
owner. Baseline titres of the upper outliers were #0.25 IU/ml,
most with a titre of #0.09 IU/ml. The history of those individuals
with the next highest titre (91 IU/ml) varied, and included seven
dogs that were born in Zenzele after October 2009.
It is unlikely that any of the dogs vaccinated by the DoA four
months prior to initiation of vaccination of the research cohort
were inadvertently included in the research cohort. The day 0
titres of the research cohort (including upper outliers ranged from
0.06–1 IU/ml with a GMT of 0.1 IU/ml) were substantially lower
than the day 90 titres of the DoA cohort (including upper outliers
ranged from 0.06–128 IU/ml with a GMT of 2.8 IU/ml).
Thirteen (20%) of the dogs vaccinated by the DoA had titres #
1 IU/ml 90 days after vaccination, of which 6 had titres,0.5 IU/
ml and four of these were non-responders (i.e. day 30 titre of ,
0.5 IU/ml). Only five dogs in the research cohort had day 0 titres
$0.5 IU/ml, and of these none appeared to have an anamnestic
response to the vaccine (day 30 titres ranged from 1.4–45 IU/ml)
(Tables S6 and S11). There were no differences in the distributions
of titres for dogs in Zenzele probably present in May 2006, when
the DoA vaccinated, and those that arrived into the population
after May 2006 (Table S12).
In the Bali research cohorts, upper outliers were defined as dogs
with day 180 titres of 11.3 IU/ml or greater (n = 4 in Kelusa;
n = 15 in Antiga). For some of these dogs, information provided by
their owner, breed, source and geographical location was
suggestive of vaccination undertaken independently by their
owner or as part of vaccination campaigns outside of Kelusa
and Antiga. Several (n = 15) unvaccinated controls had titres $
0.5 IU/ml (Tables S7, S8, S9). The titres of the unvaccinated
controls are summarised in Table S10.
Evaluation of antibody titres
Titre variations in the vaccinated dogs. The quality of the
serum samples was excellent, with only a few samples with slight to
moderate haemolysis. Most dogs in Zenzele seroconverted (97% of
the research and 92% of the DoA cohorts had titres $0.5 IU/ml
at day 30), however there was considerable variability in titres at
each time point (Figure 2). The estimated dog-dog variation
(random effect) in peak titres (quadratic model intercept) was large
(+/2 2SD 1.8–99 IU/ml) (Table S17, model 1). Excluding upper
outliers, the observed geometric mean titres (GMT) at day 30 for
the research cohort (of 15 IU/ml, Table S18) was comparable to
experimental [34,35] and field [48] studies of previously unvac-
cinated dogs. The maximum peak titre was more than double the
upper limit of the other studies (40–50 IU/ml), however those
dogs with peak titres .40 IU/ml included seven dogs born in
Zenzele after October 2009 which were unlikely to have been
vaccinated prior to commencement of the study. There was similar
variability in the titres at each time point for the Bali cohorts
(Figures 3–4; Table S17, models 3–6). See Table S13 for details of
the dogs in Zenzele that did not seroconvert to the vaccine.
Although the GMTs for the Bali cohorts were statistically
significantly higher than Zenzele (Mann-Whitney test p#0.05) for
day 180 and 360, the value of the means and modes were
comparable between cohorts at each time point (Table S14). Less
than 10% of each cohort had titres of#0.1 IU/ml at day 360. For
Zenzele, peak titres did not exceed 5.7 IU/ml for these dogs, and
three were non-responders. See Table S15 for details of the dogs in
each cohort with titres #0.1 IU/ml 360 days after vaccination.
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Between 20–40% of dogs overall had titres ,0.5 IU/ml at the last
time point. Excluding upper outliers, dogs in Zenzele with day 360
titres ,0.5 IU/ml had a statistically significantly (Mann-Whitney
test p,0.001) lower day 30 GMT (6.6 IU/ml, n = 38) compared
to dogs with day 360 titres $0.5 IU/ml (23.6 IU/ml, n = 57); this
is consistent with the correlations between time points discussed
below.
Kinetics of titres in the vaccinated dogs. In Zenzele, titres
declined rapidly between day 30 and 90, then gradually from day
90 (Figures 1–2). Log titres were closely correlated across all the
time points, including between day 30 and 360 (excluding outliers
correlation coefficient r=0.55) and day 30 and the mean log titre
for day 90, 180 and 360 (r=0.72) (Table S16). Consequently, dogs
with higher peak titres tended to have higher titres at the final time
point. The model assuming a quadratic relationship between titre
and time was a good fit, with predicted GMT for the day 30 (peak)
and 360 titres congruent with the observed means (Table S17,
model 1 and Table S18).
Peak (day 30) titres could not be extrapolated from the linear
models for Bali, but the decline in titres between 180 and 360 in
Kelusa was similar to Zenzele (Table S17, models 2–4). The GMT
for Antiga declined only marginally with time (slope p= 0.4; Table
S17, model 5), with a rate of decline less than quarter that of
Zenzele and Kelusa. Overall, the predicted GMTs were compa-
rable to the observed titres (Table S17, models 1–5 and Table
S18).
The magnitude of any decline in titre as a consequence of
extended storage time or freeze-thaw cycles was not great
compared to normal background variation. This agrees with
other studies evaluating the effect of storage time and freeze-thaw
cycles on blood proteins [76,77]. The decline in titre for 22 (88%)
of the samples did not exceed normal inter-assay variation of two-
fold or less [78].
Factors associated with variations in titre. When com-
paring the research cohorts, all models with time (points) had
lower AICs than the null models except for Antiga when upper
outliers were excluded, indicating that time after vaccination had
an effect on titre. While there were no clear patterns across the
cohorts between variations in titre and the covariates described
under Covariates in the Materials and Methods, lactation and
health status emerged as significant covariates.
For Zenzele, apart from lactation at vaccination, there were no
statistically significant (p,0.05) associations of titre with age,
gender, reproductive and health status, and body condition when
accounting for all the time points (i.e. for models of the
longitudinal data). Time and lactation were the only covariates
retained in the quadratic model with the lowest AIC, where the
negative effect of lactation was statistically significant (p#0.02)
(Table S20, model 1). When the response variable was restricted to
peak (day 30) titres, titres again varied significantly with lactation
(p#0.02) (Table S20, model 2). Overall, the GMT of lactating
dogs (,6 IU/ml) was less than half that of males and non-lactating
females. Clinical signs at the time of vaccination was also
significant (p = 0.04) when the response variable was restricted to
peak (day 30) titres but only when upper outliers were included in
the model (Table S20, model 3). Those dogs with clinical signs at
the time of vaccination had a GMT of 11 IU/ml, approximately
half that of dogs without clinical signs (21 IU/ml). When body
condition was dropped from the model, clinical signs at the time of
vaccination was marginally statistically significant (p = 0.06) (Table
Figure 2. Variations in titre in the Zenzele research cohort. Titres of all the dogs in the Zenzele research cohort. Upper outliers (i.e. the seven
dogs with day 30 titres$128 IU/ml) are excluded. The median titre (thick, horizontal line), 25th and 75th percentiles (thin horizontal lines), and either
minimum and maximum titres or 1.56 the interquartile range (dashed vertical lines) are shown for each time point after vaccination (at day 30, 90,
180 and 360). Day 0 shows the distribution of titres immediately prior to vaccination.
doi:10.1371/journal.pntd.0003160.g002
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S20, Note 4); the differences in factor levels (i.e. with and without
clinical signs at vaccination) between the two models were
comparable (9.5 IU/ml including and 8.0 IU/ml excluding body
condition).
Lactation and health status at vaccination were also the main
covariates of significance in the Bali villages. Lactation and
pregnancy were excluded from the models for Kelusa (Table S21)
given their small group sizes (Table S24) and these covariates were
not retained in any of the models for Antiga (Table S22). However,
a positive effect of lactation at vaccination was marginally
statistically significant (p= 0.07) to statistically significant (p= 0.05)
for Kelusa and Antiga combined when upper outliers were included
in the model (Table S23, model 1 and Note 2).
When generalised dermatitis at the time of vaccination was
included in the combined model, lactation was no longer significant
(Table S23, model 2). Generalised dermatitis was statistically
significant (p,0.02), although the GMT was only approximately
0.5 IU/ml less than the baseline (i.e. dogs not lactating without
dermatitis GMT ,2 IU/ml). Generalised dermatitis was retained
in models for Kelusa, but it was not statistically significant (p= 0.15)
(Table S21, model 1) even though 44 (37%) of dogs at the time of
vaccination were affected (Table S24). However, generalised
dermatitis at the time of vaccination was generally highly statistically
significant for the Antiga cohort (p#0.01) reducing the GMT by up
to half (Table S22, models 2 and 3).
Convergence errors, regardless of fitting method, precluded full
evaluation of the data set combining all three research cohorts.
Rabivet Supra 92. Of the 16 dogs vaccinated in December
2009 with Rabivet Supra 92 all had titres ,0.5 IU/ml except for
one dog at day 180 and two at day 360 sampling (Table S25).
Lagos bat virus assays. The samples were negative for
Zenzele. All the samples were negative for Bali except for one
vaccinated dog in Kelusa, with a 50% end-point titre of 1/64 upon
initial testing and 1/32 upon re-testing.
Other diagnostics. Lymphocyte counts were significantly
associated with body condition at the time of vaccination (p= 0.03)
(Table S20, model 4), however there was no association with peak
(day 30) titres (p.0.05). There were no associations between
eosinophil counts and titres at any time point.
Almost all of the dogs had intestinal parasites, primarily
Ancylostoma spp. (Table S26) [79,80]. Consequently, there was
insufficient variability to determine the effect of intestinal parasites
on immune response to vaccination. One dog was positive for
Demodex spp. on deep skin scrape.
Discussion
The longitudinal, individual-level data from this study provides
the most detailed serological data currently available for domestic
dogs in rabies endemic areas, and provides valuable support for
planning rabies vaccination programmes.
This study reinforces the importance of frequent and regular
vaccination campaigns to ensure effective vaccination coverage is
maintained. Dogs with lower peak titres had correspondingly
lower titres at the end of the study, with titres ,0.5 IU/ml at the
last time point (day 360) for 20–40% of the dogs and ,0.1 IU/ml
for 3–8% of the dogs (Table S14); the implication being an
increased susceptibility to natural exposure with time in the dogs
with low titres [27,34,37,40,46]. Robust demographic data from
these study populations indicates, two years after a pulse campaign
Figure 3. Variations in titre in the Kelusa research cohort. Titres of all the dogs in the Kelusa research cohort. Upper outliers (i.e. the four dogs
with day 180 titres of 11.3 IU/ml) are excluded. The median titre (thick, horizontal line), 25th and 75th percentiles (thin horizontal lines), and either
minimum and maximum titres or 1.56 the interquartile range (dashed vertical lines) are shown for each time point after vaccination (at day 180 and
360).
doi:10.1371/journal.pntd.0003160.g003
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which achieved 80% vaccination coverage, at least 20–45%
vaccination coverage would remain [19], which is the critical
threshold necessary to prevent rabies [24]. However, from our
model predictions (Table S17), we speculate that a substantial
proportion of the dogs remaining in Zenzele two years after
vaccination may have titres ,0.1 IU/ml, potentially dropping
effective vaccination coverage to below the critical threshold.
Models were constrained to two time points for the Bali cohorts,
but predicted similar declines in the GMT for Kelusa.
The vast majority of the dogs seroconverted following
vaccination (with a peak titre of $0.5 IU/ml), regardless of health
status. However, there was considerable variation in titres at each
time point for all the cohorts. Peak titres were not measured for the
Bali cohorts, however day 180 titres were comparable to Zenzele,
therefore it is likely that a similar proportion of dogs to Zenzele
seroconverted following vaccination. Identification of risk factors
associated with lower titres may promote targeted boostering to
maintain vaccination coverage. Clinical conditions around the
time of vaccination reduced the immune response to the vaccine in
all the cohorts; in particular, generalised dermatitis provided a
‘visible marker’ for a reduced immune response, with practical
implications for rabies control. While demodicosis was assumed to
be an important cause of generalised dermatitis associated with
immuno-suppression in Bali, the mostly negative skin scrapes
suggests that dermatophytosis may be more likely, consistent with
both the tropical climate and immuno-suppression [65,66]. This
warrants further investigation given that a substantial proportion
of the dogs (37%–46% Table S24) were affected, potentially
reducing the effectiveness of vaccination. Lactation at the time of
vaccination in Zenzele and the Bali cohorts combined was
significant statistically, however its biological significance is
unclear. Lactation is associated with loss of body condition in all
the research sites [19], consistent with immuno-suppression
observed in Zenzele. The reason for the opposite effect in Bali
cannot be readily explained [81,82]. While this incongruity may
warrant further investigation in larger study populations on
balance lactating bitches should be vaccinated, with re-vaccination
following weaning.
Our study demonstrated an advantage of community engage-
ment and door-to-door vaccine programmes over the use of simple
vaccination points. We consistently achieved vaccination coverage
above 70% through door-to-door vaccine delivery, even in Bali
where the majority of the dogs needed to be caught by net on
successive occasions. Similar coverage was achieved across the rest
of the island through door-to-door vaccine delivery in 2010 and
2011 [83]. This compares to a vaccination coverage of only 27%
through the vaccination point in Zenzele and a very low vaccine
uptake (5%) in Kelusa. The utility of vaccination points is likely to
differ between locations according to local circumstances. Similar
to other communities in Africa, Europe and central Asia where
free-roaming dogs are handleable [11,13,84,85], it is likely that the
majority of the dogs in Zenzele could have been delivered to the
vaccination point by their owners, and the low vaccination
coverage was probably the result of inadequate advertising [86]
and limited operating hours during a work/school day. Vaccine
uptake in Kelusa was, in part, affected by community awareness of
the research vaccination program, however the majority of the
dogs could not be handled by their owners or the vaccinators, thus
necessitating restraint by net [83]. The reasons for the difference in
handleability between locations are unclear. Restraint by net is
Figure 4. Variations in titre in the Antiga research cohort. Titres of all the dogs in the Antiga research cohort. Upper outliers (i.e. the fifteen
dogs with day 180 titres of 11.3 IU/ml) are excluded. The median titre (thick, horizontal line), 25th and 75th percentiles (thin horizontal lines), and
either minimum and maximum titres or 1.56the interquartile range (dashed vertical lines) are shown for each time point after vaccination (at day 180
and 360).
doi:10.1371/journal.pntd.0003160.g004
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more stressful to the dog, time consuming and costly than by leash
and muzzle. In order to improve welfare, facilitate more cost-
effective and efficient delivery of vaccines (and other prophylac-
tics), and improve evaluation of the dogs in Bali and similar
communities, extending our studies to evaluate the differences in
husbandry, environment and other factors influencing the
temperament of the dogs in the sites is warranted.
This research has generated valuable data that may contribute
to rabies control, including through improving epidemiological
models. However, understanding variation between dogs in titres
measured from field studies is challenging. Some covariates that
may impact on titres, such as lactation and health status, are
measurable, whereas others such as genetics and stress are harder
to assess in real time. Further evaluation of factors associated with
variation in immunity over time since vaccination, including both
serological responses and direct assessment of CMI, and recording
vaccine failures is warranted and may require larger populations
studied and over longer time periods.
Conclusion
This study demonstrates that the vast majority of free-roaming
dogs, in two regions of Africa and Asia where rabies is endemic,
seroconverted to rabies vaccine regardless of health status,
producing titres that exceeded 0.5 IU/ml, the level considered
necessary to protect against rabies. Declines in vaccination
coverage following a vaccination campaign occur through
mortality/emigration of vaccinated dogs and birth/immigration
of unvaccinated, susceptible dogs. Robust demographic data from
the study populations show that two years after vaccinating at least
70% of dogs during a pulse vaccination campaign, vaccination
coverage remained within 20–45% [19], the range necessary to
control rabies (Hampson 2009). However, our serological data
indicates that dogs with lower peak (day 30) titres had
correspondingly lower end point (day 360) titres. We speculate
that a proportion of vaccinated dogs remaining in the study
populations after two years will probably have titres below the
approximate threshold for protection (,0.1 IU/ml) thus dropping
effective vaccination coverage to below the critical threshold (of
20–45%). This emphasizes the importance of re-vaccinating
within two years. Vaccination of all dogs during annual campaigns
is therefore recommended as the most effective means of ensuring
that individual immunity and population coverage are both
maintained at sufficient levels to control rabies.
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